Similar Items: Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial
- Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- Regional amyloid PET asymmetry and long‐term clinical trajectory in mild cognitive impairment
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- Anti‐amyloid therapy eligibility in a longitudinal brain‐donor cohort with post mortem confirmation
- Obstacles and solutions for implementing amyloid‐targeting treatments in Europe
- Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience